Advertisement
Review| Volume 3, ISSUE 2, P109-118, 1999

Download started.

Ok

Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin b in the treatment of fungal infections in cancer patients: A review

Open ArchiveDOI:https://doi.org/10.1016/S1201-9712(99)90019-X
Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin b in the treatment of fungal infections in cancer patients: A review
Previous ArticleTyphoid fever and HIV infection: A rare disease association in industrialized countries
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The incidence of life-threatening invasive fungal infections in immunocompromised patients has increased dramatically in recent years. Candida spp other than C. albicans are increasingly being isolated, and Aspergillus infections also are on the increase, as well as infections due to previously uncommon organisms. It is likely that this phenomenon is multifactorial in origin, although the extensive use of antifungal prophylaxis may have played a role, especially for the emergence of non-albicans Candida. Amphotericin B remains the antifungal agent with the broadest spectrum of action available and is thus the standard treatment for immunocompromised patients with proven or suspected fungal infections, especially aspergillosis. However, its potential for nephrotoxicity limits its usefulness. Lipid formulations of amphotericin B may allow therapy to be administered with reduced renal toxicity. Three different lipid formulations of amphotericin B currently are available. These compounds have different pharmacokinetic properties and seem to achieve higher serum or tissue concentrations than amphotericin B. This statement is based on animal models and scattered human data. At present, there are no studies comparing the lipid formulations with each other and only a few randomized trials comparing them with conventional amphotericin B. However, a number of open clinical trials and compassionate-use protocols suggest that lipid-based forms of amphotericin B can achieve good response rates with minimal toxicity in patients with a variety of invasive mycoses, including those who have proved refractory or intolerant to previous therapy with conventional amphotericin B. Unfortunately, the cost of these compounds remains high and may represent a limiting factor to their use.

      Keywords

      References

        • Crawford S.W.
        Bone-marrow transplantation and related infections.
        Semin Respir Infect. 1993; 8: 183-190
        • Wingard R.
        Changes in the spectrum of fungal infections in bone marrow transplant patients.
        Infect Dis Clin Pract. 1994; 3: S83-S89
        • Walsh T.J.
        • Lyman T.A.
        New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases.
        in: Klastersky J. Infectious complications of cancer. Kluwer Academic Publisher, Boston, Dordrecht, London1995: 113-148
        • Meyers J.D.
        Fungal infections in bone marrow transplant patients.
        Semin Oncol. 1990; 17: 10-13
        • Abi-Said D.
        • Anaissie E.
        New emerging fungal pathogens.
        Baillieres Clin Infect Dis. 1995; 2: 71-87
        • Viscoli C.
        • Castagnola E.
        • Machetti M.
        Antifungal treatment in patients with cancer.
        J Intern Med. 1997; 242: 89-94
        • Beck-Sagué C.M.
        • Jarvis W.R.
        • National Nosocomial Infections Surveillance System
        Secular trends in the epidemiology of nosocomial fungal infections in the United States. 1980–1990.
        J Infect Dis. 1993; 167: 1247-1251
        • Grof A.
        • Shah P.M.
        • Mentzel C.
        • et al.
        Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital.
        J Infect. 1996; 33: 23-32
        • Morrison V.A.
        • Haake R.J.
        • Weisdorf D.J.
        The spectrum of non-Candida fungal infections following bone marrow transplantation.
        Medicine. 1993; 72: 78-89
        • Walsh T.J.
        • Hiemenz J.
        • Pizzo P.A.
        Editorial response: evolving risk factors for invasive fungal infections: all neutropenic patients are not the same.
        Clin Infect Dis. 1994; 18: 793-798
        • Viscoli C.
        • Castagnola E.
        Factors predisposing cancer patients to infection.
        in: Klastersky J. Infectious complications of cancer. Kluwer Academic Publisher, Boston, Dordrecht, London1995: 1-30
        • Wingard J.R.
        Importance of Candida species other than Candida albicans as pathogens in oncology patients.
        Clin Infect Dis. 1995; 20: 115-125
        • Nguyen M.H.
        • Peacock J.E.J.
        • Morris A.J.
        • et al.
        The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.
        Am J Med. 1996; 100: 617-623
        • Viscoli C.
        • Castagnola E.
        • Van Lint M.T.
        • et al.
        Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective, and randomised clinical trial.
        Eur J Cancer. 1996; 32: 814-820
        • Viscoli C.
        • Girmenia C.
        • Marinus A.
        • et al.
        An EORTC prospective, multicenter, surveillance study of candidemia in cancer patients.
        Clin Infect Dis. 1999; (in press.)
        • Abi-Said D.
        • Anaissie E.
        • Uzun O.
        • et al.
        The epidemiology of hematogenous candidiasis caused by different Candida species.
        Clin Infect Dis. 1997; 24: 1122-1128
        • Wingard J.R.
        • Merz W.G.
        • Rinaldi M.G.
        • et al.
        Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
        N Engl J Med. 1991; 325: 1274-1277
        • Wingard J.R.
        • Merz W.G.
        • Rinaldi M.G.
        • et al.
        Association of Torulopsis glabrata infection with fluconazole prophylaxis in neutropenic bone marrow transplant patients.
        Antimicrob Agents Chemother. 1993; 37: 1847-1849
        • Winston D.J.
        • Chandrasekar P.H.
        • Lazarus H.M.
        • et al.
        Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.
        Ann Intern Med. 1993; 118: 495-503
        • Goodman J.L.
        • Winston D.J.
        • Greenfeld R.A.
        • et al.
        A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.
        N Engl J Med. 1992; 326: 845-851
        • Kunova A.
        • Trupl J.
        • Dluholucky S.
        • Galova G.
        • Krcmery V.
        Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species.
        Clin Infect Dis. 1995; 21: 226-227
        • White M.H.
        • Anaissie E.J.
        • Kusne S.
        • et al.
        Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
        Clin Infect Dis. 1997; 24: 635-642
        • Denning D.W.
        • Stevens D.A.
        Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases.
        Rev Infect Dis. 1990; 12: 1147-1201
        • Viscoli C.
        • Boni L.
        • Etzioni R.
        • Seidel K.
        • Anasetti C.
        Infections in recipients of bone marrow transplant (BMT) from unrelated donors.
        in: Presented at the 8th International Symposium on Infections in the Immunocompromised Host, Davos, SwitzerlandJune 19–22, 1994
        • Gamis A.S.
        • Gudnason T.
        • Giebink G.S.
        • Ramsay N.K.C.
        Disseminated infection with Fusarium in recipients of bone marrow transplants.
        Rev Infect Dis. 1991; 13: 1077-1088
        • Rex J.H.
        • Rinaldi M.G.
        • Pfaller M.A.
        Resistance of Candida species to fluconazole.
        Antimicrob Agents Chemother. 1995; 39: 1-8
        • Rex J.H.
        • Bennet J.E.
        • Sugar A.M.
        • et al.
        A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia.
        N Engl J Med. 1994; 331: 1325-1330
        • Rex J.
        • Pfaller M.
        • Barry A.
        • Nelson P.W.
        • Webb C.D.
        Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia.
        Antimicrob Agents Chemother. 1995; 39: 40-44
        • Vanden-Bossche H.
        • Warnock D.W.
        • Dupont B.
        • et al.
        Mechanisms and clinical impact of antifungal drug resistance.
        J Med Vet Mycol. 1994; 32: 189-202
        • Gorbach S.L.
        Antimicrobial resistance in the 1990s.
        Infect Dis Clin Pract. 1996; 5: S32-S36
        • Walsh T.J.
        Evolving patterns of nosocomial and community acquired deep mycoses: analogies to other infections and implications for practitioners.
        Infect Dis Clin Pract. 1994; 3: S103-5112
        • Van't Wout J.W.
        Fungal infections and antifungal drugs: Has the age of antifungal resistance dawned?.
        Curr Opin Infect Dis. 1996; 9: 63-66
        • Lam H.H.
        • Althaus B.L.
        Antifungal prophylaxis in bone marrow transplant.
        Ann Pharmacother. 1995; 29: 921-924
        • Marr K.A.
        • White T.C.
        • van Burik J.A.H.
        • Bowden R.A.
        Development of fluconazole resistance in Candida albicans causing disseminated infection in patients undergoing marrow transplantation.
        Clin Infect Dis. 1997; 25: 908-910
        • Odds F.C.
        Resistance of yeasts to azole-derivative antifungals.
        J Antimicrob Chemother. 1993; 31: 463-471
        • Francis P.
        • Walsh T.J.
        The evolving role of flucytosine in immunocompromised patients: new insight into safety, pharmacokinetics, and antifungal therapy.
        Clin Infect Dis. 1992; 15: 1003-1018
        • DeMuri G.P.
        • Hostetter M.K.
        Resistance to antifungal agents.
        Pediatr Clin North Am. 1995; 42: 665-685
        • Scholer H.J.
        • Polak A.
        Resistance to systemic antifungal agents.
        in: Bryan L.E. Antimicrobial drug resistance. Academic Press, Orlando, Florida1984: 393-460
        • Iwata K.
        Drug resistance in human pathogenic fungi.
        Eur J Epidemiol. 1992; 8: 407-421
        • Pfaller M.A.
        • Messer S.A.
        • Hollis R.J.
        Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.
        Diagn Microbiol Infect Dis. 1994; 20: 127-133
        • Persat F.
        • Marzullo C.
        • Guyotat D.
        • Rochet R.J.
        • Piens M.A.
        Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment.
        Eur J Cancer. 1992; 28: 838-840
        • Rex J.H.
        Editorial response: catheters and candidemia.
        Clin Infect Dis. 1996; 22: 467-470
        • Gallis H.A.
        • Drew R.H.
        • Pickard W.W.
        Amphotericin B.: 30 years of clinical experience.
        Rev Infect Dis. 1990; 12: 308-329
        • Glaser V.
        Liposomal antifungals battle for market share.
        Biotechnology. 1995; 13: 728-729
        • Wong-Beringer A.
        • Jacobs R.A.
        • Guglielmo B.J.
        Lipid formulations of amphotericin B: clinical efficacy and toxicities.
        Clin Infect Dis. 1998; 27: 603-618
        • White M.H.
        • Bowden R.A.
        • Sandler E.S.
        • et al.
        Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.
        Clin Infect Dis. 1998; 27: 296-302
        • Tang C.M.
        • Bowler I.C.J.W.
        Do the new lipid formulations of amphotericin B really work?.
        Clin Microbiol Infect. 1997; 3: 283-288
        • Van Burik J.H.
        • Bowden R.A.
        Standard antifungal treatment, including role of alternative modalities to administer amphotericin.
        Baillieres Clin Infect Dis. 1995; 2: 89-109
        • Ayestarán A.
        • López R.M.
        • Montoro J.B.
        • et al.
        Pharmacokinetics of conventional formulations versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
        Antimicrob Agents Chemother. 1996; 40: 609-612
        • Hiemenz J.W.
        • Walsh T.J.
        Lipid formulations of amphotericin B: recent progress and future directions.
        Clin Infect Dis. 1996; 22: S133-S144
        • Groll A.
        • Giri N.
        • Gonzalez C.
        • et al.
        Penetration of lipid formulations of amphotericin B into cerebrospinal fluid and brain tissue.
        in: Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, TorontoSept 28–Oct 1, 1997
        • Clemons K.V.
        • Stevens D.A.
        Comparison of Fungizone, Amphotec, AmBisome and Abelcet for treatment of systemic murine cryptococcosis.
        Antimicrob Agents Chemother. 1998; 42: 899-902
        • Lister J.
        Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mycoses: the North American experience.
        Eur J Haematol. 1996; 56: 18-23
        • Kline S.
        • Larsen T.A.
        • Fieber L.
        • et al.
        Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex.
        Clin Infect Dis. 1995; 21: 1154-1158
        • Adler-Moore J.P.
        • Proffitt R.T.
        Development, characterization, efficacy and mode of action of AmBisome®, a unilamellar liposomal formulation of amphotericin B.
        J Lipid Res. 1993; 3: 429-450
        • Meunier F.
        • Prentice H.G.
        • Ringden O.L.
        Liposomal amphotericin B (AmBisome): safety data from a phase II/III/ clinical trial.
        J Antimicrob Chemother. 1991; 28: 83-91
        • Mills W.
        • Chopra R.
        • Linch D.C.
        • Goldstone A.H.
        Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients.
        Br J Haematol. 1994; 86: 754-760
        • Oppenheim B.A.
        • Herbrecht R.
        • Kusne S.
        The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses.
        Clin Infect Dis. 1995; 21: 1145-1153
        • Walsh T.J.
        • Hiemenz J.W.
        • Seibel N.
        • Anaissie E.J.
        Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
        Clin Infect Dis. 1998; 26: 1383-1396
        • Ringden O.
        • Jonsson V.
        • Hansen M.
        • Tollemar J.
        • Jacobsen N.
        Severe and common side effects of amphotericin B lipid complex (Abelcet).
        Bone Marrow Transplant. 1998; 22: 733-734
        • Wingard J.R.
        Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with lifethreatening systemic mycoses.
        Bone Marrow Transplant. 1997; 19: 343-347
        • Anaissie E.J.
        • White M.H.
        • Uzun O.
        • et al.
        Abelcet® (amphotericin B lipid complex) vs. amphotericin B for treatment of invasive candidiasis: a prospective, randomised multicentre trial.
        in: Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San FranciscoSept 17–20, 1995
        • Walsh T.J.
        • Whitcomb P.
        • Piscitelli S.
        • et al.
        Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
        Antimicrob Agents Chemother. 1997; 41: 1944-1948
        • Mehta J.
        • Kelsey S.
        • Chu P.
        • et al.
        Amphotericin B lipid complex for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
        Bone Marrow Transplant. 1997; 20: 39-43
        • Lister J.
        Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy [Abstract].
        Blood. 1994; 84: 306
        • Ringden O.
        • Meunier F.
        • Tollemar J.
        • et al.
        Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.
        J Antimicrob Chemother. 1991; 28: 73-82
        • Chopra R.
        • Blair S.
        • Strang J.
        • et al.
        Liposomal amphotericin B (AmBisome) in the treatment of fungal infection in neutropenic patients.
        J Antimicrob Chemother. 1991; 28: 93-104
        • International Antimicrobial Therapy Cooperative Group E
        Empiric antifungal therapy in febrile granulocytopenic patients.
        Am J Med. 1989; 86: 668-672
        • Winston D.J.
        • Hathorn J.
        • Schuster M.
        Fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients: results of a randomized multicentre trial.
        in: Presented at the 20th meeting of the International Congress of Chemotherapy, Sydney, AustraliaJune 29–July 3, 1997
        • Prentice H.G.
        • Hann I.M.
        • Herbrecht R.
        • et al.
        A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
        Br J Haematol. 1997; 98: 711-718
        • Walsh T.
        • Bodensteiner J.
        • Hiemenz S.
        • et al.
        A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
        in: Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, TorontoSept 28–Oct 1, 1997
        • British Medical Association
        British National Formulary.
        Royal Pharmaceutical Society of Great Britain, London1996
      73. Marini L. Organizzazione Editoriale Medico Farmaceutica. Italian Directory of Drugs and Manufacturers, Milan, Italy1998

      Article info

      Footnotes

      ☆Supported in part by the Ministero dell'Università e della Ricerca Scientifica e Technologica (MURST) and the University of Genoa, Italy.

      Identification

      DOI: https://doi.org/10.1016/S1201-9712(99)90019-X

      Copyright

      © 1999 Published by Elsevier Inc.

      User license

      Elsevier user license |
      How you can reuse Information Icon
      Elsevier user license

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Text & data mine
      • Translate the article

      Not Permitted

      • Reuse portions or extracts from the article in other works
      • Redistribute or republish the final article
      • Sell or re-use for commercial purposes

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX